Last: | $22.64 |
---|---|
Change Percent: | -0.49% |
Open: | $22.53 |
Close: | $22.64 |
High: | $22.73 |
Low: | $22.42 |
Volume: | 140,571 |
Last Trade Date Time: | 04/23/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$22.64 | $22.53 | $22.64 | $22.73 | $22.42 | 140,571 | 04-23-2024 |
$22.42 | $22.32 | $22.42 | $22.54 | $22.3001 | 111,248 | 04-22-2024 |
$22.1554 | $22.2745 | $22.1554 | $22.4532 | $22.1256 | 128,556 | 04-19-2024 |
$22.4 | $22.5 | $22.4 | $22.555 | $22.38 | 74,556 | 04-18-2024 |
$22.41 | $22.57 | $22.41 | $22.62 | $22.41 | 107,224 | 04-17-2024 |
$22.43 | $22.44 | $22.43 | $22.555 | $22.31 | 79,187 | 04-16-2024 |
$22.38 | $22.98 | $22.38 | $23.17 | $22.36 | 153,558 | 04-15-2024 |
$22.84 | $23.35 | $22.84 | $23.35 | $22.8 | 136,387 | 04-12-2024 |
$23.4 | $23.45 | $23.4 | $23.52 | $23.28 | 88,320 | 04-11-2024 |
$23.34 | $23.47 | $23.34 | $23.52 | $23.28 | 113,476 | 04-10-2024 |
$23.68 | $23.5 | $23.68 | $23.72 | $23.4 | 194,229 | 04-09-2024 |
$23.52 | $23.37 | $23.52 | $23.5599 | $23.35 | 104,712 | 04-08-2024 |
$23.3 | $23.16 | $23.3 | $23.44 | $23.16 | 98,803 | 04-05-2024 |
$23.2 | $23.47 | $23.2 | $23.59 | $23.09 | 117,832 | 04-04-2024 |
$23.42 | $23.4 | $23.42 | $23.5699 | $23.4 | 118,985 | 04-03-2024 |
$23.44 | $23.24 | $23.44 | $23.6099 | $23.21 | 131,788 | 04-02-2024 |
$23.52 | $23.55 | $23.52 | $23.64 | $23.4601 | 106,542 | 04-01-2024 |
$23.6 | $23.49 | $23.6 | $23.7 | $23.46 | 143,571 | 03-29-2024 |
$23.6 | $23.49 | $23.6 | $23.7 | $23.46 | 143,571 | 03-28-2024 |
$23.4 | $23.23 | $23.4 | $23.4 | $23.17 | 88,200 | 03-27-2024 |
News, Short Squeeze, Breakout and More Instantly...
Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest Company Name:
EVT Stock Symbol:
NYSE Market:
HAMBURG, GERMANY / ACCESSWIRE / April 23, 2024 / The Supervisory Board of Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) has appointed Dr Christian Wojczewski as the Company's new Chief Executive Officer ("CEO"), effective 01 July 2024. The election was un...
COLLABORATION LEVERAGES VARIANT BIO'S CUTTING-EDGE GENOMIC DISCOVERY PLATFORM AND EVOTEC'S INTEGRATED END-TO-END R&D PLATFORM AND DISEASE AREA EXPERTISE TO ADDRESS UNMET MEDICAL NEED IN FIBROTIC INDICATIONS COMMERCIAL TERMS INCLUDE RESEARCH FUNDING AND MILESTONES AND/OR ROYALTY PAYMENTS ...
HAMBURG, GERMANY / ACCESSWIRE / April 17, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will announce its financial results for 2023 on Wednesday, 24 April 2024. The Company is going to hold a conference call to discuss the results as well as prov...